Seltorexant
Seltorexant is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against orexin receptor type 2. In addition, it is known to target orexin/Hypocretin receptor type 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
34 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | 5 | 2 | 4 | — | 1 | 12 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 5 | 2 | 4 | — | 1 | 12 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 5 | 2 | 4 | — | 1 | 12 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | 1 | 2 | — | — | — | 3 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 14 | — | — | — | — | 14 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 1 | — | — | — | — | 1 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | 1 | — | — | — | — | 1 |
| Apnea | D001049 | — | R06.81 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Seltorexant |
| INN | seltorexant |
| Description | Seltorexant, also known by its developmental code names MIN-202 and JNJ-42847922, is an orexin antagonist medication which is under development for the treatment of depression and insomnia. It is a selective antagonist of the orexin OX2 receptor (2-SORA). The medication is taken by mouth. As of February 2022, seltorexant is in phase 3 clinical trials for treatment of major depressive disorder (MDD) and phase 2 trials for treatment of insomnia. It was also under investigation for the treatment of sleep apnea, but no recent development has been reported for this indication. Seltorexant is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceuticals.
|
| Classification | Small molecule |
| Drug class | Orexin antagonist |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cc(C)nc(N2CC3CN(C(=O)c4c(F)cccc4-n4nccn4)CC3C2)n1 |
Identifiers
| PDB | — |
| CAS-ID | 1452539-75-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3597971 |
| ChEBI ID | — |
| PubChem CID | 86278359 |
| DrugBank | — |
| UNII ID | AIS8N3O50B (ChemIDplus, GSRS) |
Target
Alternate
HCRTR1
HCRTR1
Organism
Homo sapiens
Gene name
HCRTR1
Gene synonyms
NCBI Gene ID
Protein name
orexin/Hypocretin receptor type 1
Protein synonyms
hypocretin (orexin) receptor 1, Hypocretin receptor type 1, orexin receptor 1, Orexin receptor type 1, Ox-1-R, Ox1-R, Ox1R
Uniprot ID
Mouse ortholog
Hcrtr1 (230777)
orexin/Hypocretin receptor type 1 (Q80T45)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 125 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use